Lista de obras - Marina Garassino - Dominio Público Uruguay

A lesson from vorinostat in pleural mesothelioma

artículo científico publicado en 2015

A mono-institutional prospective study on the effectiveness of a specialist psychotherapeutic intervention (POI) started at the diagnosis of cancer ⬇️

artículo científico publicado el 22 de enero de 2011

ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations

artículo científico publicado en 2016

Across the universe of K-RAS mutations in non-small-cell-lung cancer.

artículo científico publicado en 2014

Afatinib for lung cancer: let there be light?

artículo científico publicado en 2014

Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?

artículo científico publicado en 2016

Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors

artículo científico publicado en 2014

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.

artículo científico publicado en 2015

Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?

artículo científico publicado en 2016

Challenging Lung Carcinoma with Coexistent ΔNp63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells.

artículo científico publicado en 2015

Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial data

artículo científico publicado en 2015

Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules

artículo científico publicado en 2016

Diagnosis and management of typical and atypical lung carcinoids

artículo científico publicado en 2016

Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge

artículo científico publicado en 2015

Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?

artículo científico publicado en 2014

Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients

article

Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.

artículo científico publicado en 2013

Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections

artículo científico

EGFR mutations and EGFR tyrosine kinase inhibitors.

artículo científico publicado en 2015

Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.

artículo científico publicado en 2013

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future

artículo científico publicado en 2016

Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer

artículo científico publicado en 2013

Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer

G48A, a New KRAS Mutation Found in Lung Adenocarcinoma.

artículo científico publicado en 2016

Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.

artículo científico publicado en 2016

Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet.

artículo científico publicado en 2016

Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations

artículo científico publicado en 2014

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy

artículo científico publicado en 2015

Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.

artículo científico publicado en 2013

Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis.

artículo científico publicado en 2010

Maintenance therapy in NSCLC: why? To whom? Which agent? ⬇️

artículo científico publicado en 2011

Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers

artículo científico publicado en 2013

Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer

artículo científico publicado en 2015

Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.

artículo científico publicado en 2012

New anti-emetic treatments.

artículo científico publicado en 2007

New findings on thymic epithelial tumors: Something is changing.

artículo científico publicado en 2015

New strategies in colon cancer adjuvant therapy

artículo científico publicado en 2006

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

artículo científico publicado en 2015

ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology

artículo científico publicado en 2016

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

artículo científico publicado en 2016

Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.

artículo científico publicado en 2008

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis

artículo científico publicado en 2010

Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

artículo científico publicado en 2016

Perioperative or postoperative therapy for resectable gastric cancer?

artículo científico publicado en 2008

Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC.

artículo científico publicado en 2015

Predicting response of molecular targeted therapies: a still possible challenge?

artículo científico publicado en 2008

Predictive models in palliative care.

artículo científico publicado en 2009

Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.

artículo científico publicado en 2013

Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

artículo científico publicado en 2012

Response of thymoma to cetuximab

scientific article published on 01 May 2007

Reversible palpebral ptosis following oxaliplatin infusion.

artículo científico publicado en 2007

Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis.

artículo científico publicado en 2010

Role of Cetuximab in the Treatment of Patients With NSCLC: Are We Throwing Out the Baby With the Bath Water?

scientific article published on 28 June 2010

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)

artículo científico publicado en 2015

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

artículo científico publicado en 2011

Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?

artículo científico publicado en 2008

Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem.

artículo científico publicado en 2016

Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?

artículo científico publicado en 2015

Targeted therapies in small cell lung cancer: a review

artículo científico publicado en 2010

Targeted therapy-induced diarrhea: A review of the literature.

artículo científico

Targeting the MET gene for the treatment of non-small-cell lung cancer

artículo científico publicado en 2013

Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.

artículo científico publicado en 2011

The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs

artículo científico publicado en 2016

The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations

artículo científico publicado en 2022

The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers

artículo científico

Thymoma and thymic carcinomas

artículo científico publicado en 2016

To target or not to target, that is the question.

artículo científico publicado en 2013

Treatment of lung large cell neuroendocrine carcinoma.

artículo científico publicado en 2016

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

artículo científico publicado en 2015

[Locoregional therapy in hepatic metastases of colorectal cancer]

artículo científico publicado en 2001

ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization

artículo científico publicado en 2013

Lista de obras de Marina Garassino

A lesson from vorinostat in pleural mesothelioma

A mono-institutional prospective study on the effectiveness of a specialist psychotherapeutic intervention (POI) started at the diagnosis of cancer ⬇️

ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations

Across the universe of K-RAS mutations in non-small-cell-lung cancer.

Afatinib for lung cancer: let there be light?

Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?

Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.

Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?

Challenging Lung Carcinoma with Coexistent ΔNp63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells.

Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial data

Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules

Diagnosis and management of typical and atypical lung carcinoids

Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge

Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?

Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients

Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.

Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections

EGFR mutations and EGFR tyrosine kinase inhibitors.

Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future

Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer

Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer

G48A, a New KRAS Mutation Found in Lung Adenocarcinoma.

Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.

Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet.

Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy

Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.

Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis.

Maintenance therapy in NSCLC: why? To whom? Which agent? ⬇️

Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers

Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer

Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.

New anti-emetic treatments.

New findings on thymic epithelial tumors: Something is changing.

New strategies in colon cancer adjuvant therapy

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis

Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

Perioperative or postoperative therapy for resectable gastric cancer?

Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC.

Predicting response of molecular targeted therapies: a still possible challenge?

Predictive models in palliative care.

Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.

Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

Response of thymoma to cetuximab

Reversible palpebral ptosis following oxaliplatin infusion.

Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis.

Role of Cetuximab in the Treatment of Patients With NSCLC: Are We Throwing Out the Baby With the Bath Water?

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?

Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem.

Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?

Targeted therapies in small cell lung cancer: a review

Targeted therapy-induced diarrhea: A review of the literature.

Targeting the MET gene for the treatment of non-small-cell lung cancer

Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.

The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs

The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations

The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers

Thymoma and thymic carcinomas

To target or not to target, that is the question.

Treatment of lung large cell neuroendocrine carcinoma.

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

[Locoregional therapy in hepatic metastases of colorectal cancer]

ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization